ArticleAmerican journal of respiratory and critical care medicine2022
Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial.
Open access · hybridAbstract readComparative Study
In one paragraph
Article in American journal of respiratory and critical care medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 68 citations in OpenAlex.
- Inhaled treprostinil in pulmonary hypertension associated with COPD: PERFECT study results.The European respiratory journal · 2024Trial
- Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study.The European respiratory journal · 2023Trial
- ERS Congress 2025: highlights from the Pulmonary Vascular Diseases Assembly.ERJ open research · 2026Article
- Pulmonary hypertension associated with interstitial lung disease: a state-of-the-art review.The European respiratory journal · 2026Review
- A Phase 2 Study of the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease.Pulmonary circulation · 2026Article
- Treatment of systemic sclerosis-associated pulmonary hypertension with and without interstitial lung disease and its impact on survival: a large cohort study of the German network for systemic sclerosis.Rheumatology (Oxford, England) · 2026Article
- Real-World Outcomes of Inhaled Treprostinil in Pulmonary Hypertension Related to Interstitial Lung Disease: A Multicenter, Retrospective Analysis.Journal of cardiovascular development and disease · 2026Article
- Exploring the therapeutic landscape of pulmonary hypertension associated with interstitial lung disease, with a focus on idiopathic pulmonary fibrosis: a narrative review.Frontiers in pharmacology · 2026Review
- Review
- Invasive Cardiopulmonary Exercise Testing Identifies Distinctive Hemodynamic Phenotypes in Patients with Interstitial Lung Disease and Exercise Intolerance.Respiration; international review of thoracic diseases · 2026Article
- Inhaled treprostinil improves cardiac output during exertion in interstitial lung disease.The European respiratory journal · 2025Article
- Real-World Comparison of Patients With PH-ILD Initiating Inhaled Treprostinil Versus Patients Who Remain Untreated.Pulmonary circulation · 2025Article
- Sotatercept for Connective Tissue Disease-Associated Pulmonary Arterial Hypertension with Concomitant Interstitial Lung Disease: Efficacy and Safety Insights.Journal of clinical medicine · 2025Article
- Idiopathic Pulmonary Fibrosis, Today and Tomorrow: Certainties and New Therapeutic Horizons.Pulmonary therapy · 2025Review
- Post lung-transplant predictive value of thermodilution vs estimated Fick cardiac output measurement.JHLT open · 2025Article
- Review of the Diagnosis and Management of Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH).Journal of clinical medicine · 2025Review
- Xenon-129 magnetic resonance imaging and spectroscopy detects response to therapy in pulmonary hypertension.The European respiratory journal · 2025Article
- Inhaled treprostinil in group 3 pulmonary hypertension associated with lung disease: results of the INCREASE and PERFECT studies.Breathe (Sheffield, England) · 2025Article
- Shining a spotlight on pulmonary hypertension associated with interstitial lung disease care: The latest advances in diagnosis and treatment.Journal of managed care & specialty pharmacy · 2025Review
- Systematic evaluation of subgroup analyses of inhaled treprostinil in pulmonary hypertension due to interstitial lung disease.PloS one · 2025Article
Corrections and comments
- Commented on by
- Commented on byReply to Jin2022
- Commented on by
Authors and funding
10 authors at 8 institutions in 1 country.
Steven D NathanAdvanced Lung Disease and Lung Transplant Program, Inova Fairfax Hospital, Falls Church, Virginia.ORCID 0000-0002-6270-1617
Victor F TapsonDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, California.ORCID 0000-0001-9708-1457
Jean ElwingDepartment of Pulmonary and Critical Care Medicine, College of Medicine, University of Cincinnati, Cincinnati, Ohio.ORCID 0000-0001-6199-1707
Franz RischardDivision of Pulmonary and Critical Care Medicine, Department of Medicine, University of Arizona, Tucson, Arizona.ORCID 0000-0002-6861-8304
Jinesh MehtaPulmonary Medicine, Cleveland Clinic, Cleveland, Ohio.
Shelley ShapiroCardiology Section, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California.
Eric ShenUnited Therapeutics Corporation, Research Triangle Park, North Carolina; and.ORCID 0000-0001-5621-6570
Chunqin DengUnited Therapeutics Corporation, Research Triangle Park, North Carolina; and.ORCID 0000-0002-5641-4101
Peter SmithUnited Therapeutics Corporation, Research Triangle Park, North Carolina; and.ORCID 0000-0002-2051-7774
Aaron WaxmanPulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0000-0001-7797-0361
Triangle · USBrigham and Women's Hospital · USCedars-Sinai Medical Center · USCleveland Clinic · USInova Fairfax Hospital · USUniversity of Arizona · USUniversity of California, Los Angeles · USUniversity of Cincinnati Medical Center · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Disease ProgressionAdministration, InhalationAgedAntihypertensive AgentsEpoprostenolFemaleHealthy VolunteersHumansHypertension, PulmonaryLongitudinal StudiesLung Diseases, InterstitialMaleMiddle AgedTreatment OutcomeAntihypertensive AgentsEpoprostenolinterstitial lung diseaseprostacyclinpulmonary hypertension
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.